PDF(Pubmed)
Abstract：
BACKGROUND: There is a lack of robust prognostic markers for upper gastrointestinal (GI) tract cancers, including esophageal, gastric, and esophagogastric junction cancers. T cell immunoglobulin and mucin-domain containing-3 (TIM3) plays a key immunomodulatory role and is linked to the prognosis of various cancers. However, the significance of TIM3 in upper GI tract tumors is still uncertain.
OBJECTIVE: To investigate the prognostic value of TIM3 expression in upper GI tract tumors.
METHODS: A literature search was conducted on the PubMed, Embase, and Web of Science databases for relevant studies published until June 2023. After screening and quality assessment, studies that met the criteria were included in the meta-analysis. Statistical methods were used for the pooled analysis to assess the association of TIM3 expression in upper GI tract tumors with the prognosis and clinicopathological parameters. The results were reported with the hazard ratio (HR) and 95% confidence interval (CI).
RESULTS: Nine studies involving 2556 patients with upper GI tract cancer were included. High TIM3 expression was associated with a worse prognosis in upper GI tract cancer (HR: 1.17, 95%CI: 1.01-1.36). Positive expression of TIM3 in gastric cancer was correlated with the T and N stage, but the difference was not statistically significant. However, TIM3 overexpression was significantly correlated with the TNM stage (odds ratio: 1.21, 95%CI: 0.63-2.33; P < 0.05). TIM3 expression showed no association with the other clinicopathological parameters.
CONCLUSIONS: High expression of TIM3 in the upper GI tract cancer is associated with a worse prognosis and advanced T or N stages, indicating its potential value as a prognostic biomarker. These findings may provide a basis for the personalized treatment of upper GI tract cancers.
OBJECTIVE: To investigate the prognostic value of TIM3 expression in upper GI tract tumors.
METHODS: A literature search was conducted on the PubMed, Embase, and Web of Science databases for relevant studies published until June 2023. After screening and quality assessment, studies that met the criteria were included in the meta-analysis. Statistical methods were used for the pooled analysis to assess the association of TIM3 expression in upper GI tract tumors with the prognosis and clinicopathological parameters. The results were reported with the hazard ratio (HR) and 95% confidence interval (CI).
RESULTS: Nine studies involving 2556 patients with upper GI tract cancer were included. High TIM3 expression was associated with a worse prognosis in upper GI tract cancer (HR: 1.17, 95%CI: 1.01-1.36). Positive expression of TIM3 in gastric cancer was correlated with the T and N stage, but the difference was not statistically significant. However, TIM3 overexpression was significantly correlated with the TNM stage (odds ratio: 1.21, 95%CI: 0.63-2.33; P < 0.05). TIM3 expression showed no association with the other clinicopathological parameters.
CONCLUSIONS: High expression of TIM3 in the upper GI tract cancer is associated with a worse prognosis and advanced T or N stages, indicating its potential value as a prognostic biomarker. These findings may provide a basis for the personalized treatment of upper GI tract cancers.
摘要：
背景：上消化道（GI）癌缺乏可靠的预后标志物，包括食道,胃,和食管胃结合部癌。T细胞免疫球蛋白和含粘蛋白结构域3（TIM3）起着关键的免疫调节作用，并与各种癌症的预后有关。然而,TIM3在上消化道肿瘤中的意义仍不确定。
目的：探讨TIM3表达在上消化道肿瘤中的预后价值。
方法：在PubMed上进行了文献检索，Embase,和WebofScience数据库的相关研究发表到2023年6月。经过筛选和质量评估，符合标准的研究纳入荟萃分析.统计方法用于汇总分析，以评估上胃肠道肿瘤中TIM3表达与预后和临床病理参数的相关性。结果以风险比（HR）和95％置信区间（CI）报告。
结果：纳入了9项研究，涉及2556例上消化道肿瘤患者。高TIM3表达与上消化道癌预后差相关(HR:1.17,95CI:1.01-1.36)。TIM3在胃癌中的阳性表达与T、N分期相关,但差异无统计学意义。然而,TIM3过表达与TNM分期显著相关(比值比:1.21,95CI:0.63-2.33;P<0.05)。TIM3的表达与其他临床病理参数无关。
结论：TIM3在上消化道肿瘤中的高表达与预后差和晚期T或N分期相关。表明其作为预后生物标志物的潜在价值。这些发现可能为上胃肠道癌症的个性化治疗提供基础。
目的：探讨TIM3表达在上消化道肿瘤中的预后价值。
方法：在PubMed上进行了文献检索，Embase,和WebofScience数据库的相关研究发表到2023年6月。经过筛选和质量评估，符合标准的研究纳入荟萃分析.统计方法用于汇总分析，以评估上胃肠道肿瘤中TIM3表达与预后和临床病理参数的相关性。结果以风险比（HR）和95％置信区间（CI）报告。
结果：纳入了9项研究，涉及2556例上消化道肿瘤患者。高TIM3表达与上消化道癌预后差相关(HR:1.17,95CI:1.01-1.36)。TIM3在胃癌中的阳性表达与T、N分期相关,但差异无统计学意义。然而,TIM3过表达与TNM分期显著相关(比值比:1.21,95CI:0.63-2.33;P<0.05)。TIM3的表达与其他临床病理参数无关。
结论：TIM3在上消化道肿瘤中的高表达与预后差和晚期T或N分期相关。表明其作为预后生物标志物的潜在价值。这些发现可能为上胃肠道癌症的个性化治疗提供基础。
